

Phone: 1-800-809-1265 Fax: 1-866-872-8920

Referral Status:	MRN:	
New referral	Order change	Order Renewal
Patient preferred clinic:		

Leqvio® (inclisiran) Standard Plan of Treatment

PATIENT DEMOGRAPH	IICS:						
Date of Referral:				Patient's Phone:			
Patient Name:				Address:			
Date of Birth:				City, State, Zip:			
Height in inches:	Weight:	LB o	r KG	Gender:	Allergies:	See list	NDKA

E78.00 - Pure hypercholesterolemia	125.110 - Atherosclerotic heart disease of native coronary artery with		
	unstable angina pectoris		
E78.01 - Familial hypercholesterolemia	I25.111 - Atherosclerotic heart disease of native coronary artery with		
	angina pectoris with documented spasm		
E78.2 - Mixed hyperlipidemia	125.118 - Atherosclerotic heart disease of native coronary artery with other		
	forms of angina pectoris		
E78.49 - Other hyperlipidemia, familial combined hyperlipidemia	125.119 - Atherosclerotic heart disease of native coronary artery with		
	unspecified angina pectoris		
E78.5 - Hyperlipidemia, unspecified	125.700 - Atherosclerosis or coronary artery bypass graft(s), unspecified,		
	with unstable angina pectoris		
E78.9 - Disorder of lipoprotein metabolism, unspecfified	125.701 - Atherosclerosis or coronary artery bypass graft(s), unspecified,		
	with angina pectoris with documented spasm		
125.10 - Atherosclerotic heart disease of native coronary artery	- Other:		
without angina pectoris			

		DLFUNL:		
1	Insurance information	IF NO:	IF YES	:
2				NJECTION DATE:
3	Full medication list	WASHOUT FROM PREVIOUS	NEXT I	NJECTION DATE:
4	T · · · · · · · · · · · · · · · · · · ·		IF OR	DER CHANGE:
5	Baseline Lipid Panel			
6				Continue current order until insurance approved

MEDICATION ORDERS:

NOTE: Leqvio[®] is Indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (ASCVD), who require additional lowering of low-density lipoprotein cholesterol (LDL-C).

DOSE/FREQUENCY:

Induction: Administer Leqvio[®] 284mg/1.5ml via subcutaneous injection at day 0, month 3 and then every 6 months Maintenance: Administer Leqvio[®] 284mg/1.5ml via subcutaneous injection every 6 months Instruction: Administer subcutaneously into the abdomen, upper arm, or thigh.

SPECIAL ORDERS:

Refills x 12 months unless noted otherwise here:

ADVERSE REACTION & ANAPHYLAXIS ORDERS:

Administer acute infusion and anaphylaxis medications per Palmetto Infusion standing adverse reaction orders, which can be found at our website or scan here.



PRESCRIBER INFORMATION:	
PROVIDER NAME:	PHONE:
ADDRESS:	FAX:
CITY, STATE, ZIP:	NPI:
PRESCRIBER SIGNATURE: (No stamp signatures)	DATE
Dispense as written/Brand medically necessary	/ Substitution permitted